Review of immunosuppression for lung transplantation: Novel drugs, new uses for conventional immunosuppressants, and alternative strategies

Clinics in Chest Medicine

Volumn 18, Issue 2, 1997, Pages 353-366

  Hausen, B ^a   Morris, R E ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHILIN; CYCLOSPORIN A; FK 506 BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; METHOXSALEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEW DRUG; PREDNISONE; RAPAMYCIN; TACROLIMUS; TERIFLUNOMIDE; THYMOCYTE ANTIBODY;

AEROSOL; BRONCHIOLITIS; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG TRANSPLANTATION; LYMPH NODE IRRADIATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; PUVA; REVIEW; SIDE EFFECT;

EID: 0030994330     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(05)70384-1     Document Type: Article

References (127)

1. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection: European FK506 Multicentre Liver Study Group Lancet 344 1994 423
2. European Mycophenolate Mofetil Cooperative Study Group Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection Lancet 345 1995 1321
3. O.A. Afolabi G. Parry M.D. Healy The role of total lymphoid irradiation (TLI) in the treatment of obliterative bronchiolitis—2 years on J Heart Lung Transplant 15 1996 S102
4. A.C. Auison E.M. Eugui Inhibition of de novo purine and pyrimidine synthesis as immunosuppressive drugs Transplant Proc 25 1993 8
5. C. Alsberg O.F. Black Contribution to the study of maize deterioration US Dept of Agriculture, Bureau of Plant Industry Bulletin 270 1913 7 48
6. H. Azuma J. Binder U. Heemann Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts Transplantation 59 1995 460
7. R.R. Bartlett M. Dimitrijevic T. Mattar Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection Agents Actions 32 1991 10
8. R.R. Bartlett R. Schleyerbach Immunopharmacological profile of a novel isoxazole derivative, HWA486, with potential antirheumatic activity—1. Disease-modifying action on adjuvant arthritis of the rat Int J Immunopharmacol 7 1985 7
9. W.O. Bechstein M. Schilling D.M. Steele RS-61443/cyclosporine combination therapy prolongs canine liver allograft survival Transplant Proc 25 1993 702
10. T. Brazelton R.E. Morris Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: Tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide Curr Opin Immunol 8 1996 710 720
11. R.Y. Calne D.S. Collier S. Lim Rapamycin for immunosuppression in organ allografting Lancet 2 1989 227
12. W. Cao P. Mohacsi R. Shorthouse Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506 Transplantation 59 1995 390
13. W.W. Cao P.N. Kao A.C. Chao Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides J Heart Lung Transplant 14 1995 1016
14. H.M. Cherwinski D. McCarley R. Schatzman The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism J Pharmacol Exp Ther 272 1995 460
15. A.S. Chong K. Rezai H.M. Gebel Effects of leflunomide and other immunosuppressive agents on T-cell proliferation in vitro Transplantation 61 1996 140
16. U. Christians F. Braun M. Schmidt Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver-graft recipients Clin Chem 38 1992 2025
17. U. Christians M. Sattler H.M. Schiebel Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin Drug Metab Dispos Biol Fate Chem 20 1992 186
18. A.M. D'Alessandro M. Rankin J. McVey Prolongation of canine intestinal allograft survival with RS-61443, cyclosporine, and prednisone Transplantation 55 1993 695
19. R. Dall Amico U. Livi G. Montini Photopheresis as adjuvant treatment of heart transplant (HTx) patients with multiple rejections J Heart Lung Transplant 13 1994 S81
20. J.P. Davis G.A. Cain W.J. Pitts The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase Biochemistry 35 1996 1270
21. R.D. Davis Jr M.K. Pasque Pulmonary transplantation Ann Surg 221 1995 14
22. J.F. Di Joseph S.N. Sehgal Functional and histopathologic effects of rapamycin on mouse kidney Immunopharmacol Immunotoxicol 15 1993 45
23. J.F. Di Joseph R.N. Sharma J.Y. Chang The effect of rapamycin on kidney function in the SpragueDawley rat Transplantation 53 1992 507
24. V.C. Dias J. Lucien D.F. Le Gatt Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography Ther Drug Monit 17 1995 84
25. R.D. Dowling M. Zenati G.J. Burckart Aerosolized cyclosporine as single-agent immunotherapy in canine lung allografts Surgery 108 1990 198
26. M. Dusmet J. Maurer T. Winton Methotrexate in the treatment of bronchiolitis obliterans syndrome J Heart Lung Transplant 15 1996 S102
27. C.P. Eng J. Gullo-Brown J.Y. Chang Inhibition of skin-graft rejection in mice by rapamycin: A novel immunosuppressive macrolide Transplant Proc 23 1991 868
28. M.A. Evans P.J. Schomberg R.J. Rodeheffer Total lymphoid irradiation: A novel and successful therapy for resistant cardiac allograft rejection Mayo Clin Proc 67 1992 785
29. L.D. Fairbanks M. Bofill K. Ruckermann Importance of ribonucleotide availability to proliferating T lymphocytes from healthy humans J Biol Chem 270 1995 29682
30. M.J. Fealy W.S. Umansky K.D. Bickel Efficacy of rapamycin and FK 506 in prolonging rat hind-limb allograft survival Ann Surg 21 1994 88
31. N. Feuerstein D. Huang M.B. Prystowsky Rapamycin selectively blocks interleukin-2–induced proliferating cell nuclear antigen gene expression in T lymphocyte. Evidence for inhibition of CREB/ATF binding activities J Biol Chem 270 1995 9454
32. W.H. Frist V.J. Biggs Chronic myelogenous leukemia after lymphoid irradiation and heart transplantation Ann Thorac Surg 57 1994 214
33. W.H. Frist A.W. Winterland E.B. Gerhardt Total lymphoid irradiation in heart transplantation: Adjunctive treatment for recurrent rejection Ann Thorac Surg 48 1989 863
34. T. Fujisawa Y. Saitoh N. Urabe Dose study of the immunosuppression of FK 506 in canine lung allo-transplantation Surg Today 23 1993 338
35. Girgis R.E. Tu I. Berry G.J. Risk factors for the development of obliterative bronchiolitis after lung transplantation J Heart Lung Transplant 1996 in press
36. Gonschior A.K. Christians U. Winkler M. Tacrolimus (FK506) metabolite pattern in blood from liver and kidney transplant patients Clin Chem 1996 in press
37. S. Greene K. Watanabe J. Braatz-Trulson Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide Biochem Pharmacol 50 1995 861
38. B. Gosio Ricerche batteriologiche e chimiche sulle alterazoni del mais Rivista d'Igiene e Sanita Pubblica Ann 7 1896 825 868
39. B.P. Griffith K. Bando R.L. Hardesty A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation Transplantation 57 1994 848
40. C.R. Gross K. Savik R.M. Bolman III Long-term health status and quality-of-life outcomes of lung transplant recipients Chest 108 1995 1587
41. S. Hasegawa H. Yokomise T. Hirai Combination use of suboptimal dose of FK 506 and cyclosporine in canine lung transplantation J Thorac Cardiovasc Surg 104 1992 1340
42. G. He V.C. McAlister T.D. Lee Oral leflunomide prevents small bowel allograft rejection in the rat Transplant Proc 26 1994 1613
43. F. Heshmati R. Guillemain A. Achkar Treatment of organ graft rejection by extracorporeal photochemotherapy Ann Med Interne Paris 145 1994 312
44. T. Hirai T.K. Waddell J.D. Puskas Prolonged lung allograft survival with a short course of FK 506 J Thorac Cardiovasc Surg 105 1993 1
45. K. Hisatomi T. Isomura M. Ohashi Effect of dose of cyclosporine or FK506 and antithrombotic agents on cardiac allograft vascular disease in heterotopically transplanted hearts in rats J Heart Lung Transplant 14 1995 113
46. S.A. Hunt S. Strober R.T. Hoppe Total lymphoid irradiation for treatment of intractable cardiac allograft rejection J Heart Lung Transplant 10 1991 211
47. H. Ihara D. Shinkuma Y. Ichikawa Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients—importance of trough level as a practical indicator Int J Urol 2 1995 151
48. H. Izutani S. Miyagawa G. Matsumiya Graft coronary arteriosclerosis in rat heart transplant model with FK 506 short-term administration Transplant Proc 27 1995 579
49. W.J. Jusko A.W. Thomson J. Fung Consensus document: Therapeutic monitoring of tacrolimus (FK-506) Ther Drug Monit 17 1995 606
50. A. Kawai I.L. Paradis R.J. Keenan Chronic rejection in heart–lung transplant recipients: The relationship between obliterative bronchiolitis and coronary artery disease Transplant Proc 27 1995 1288
51. R.J. Keenan A.J. Duncan S.A. Yousem Improved immunosuppression with aerosolized cyclosporine in experimental pulmonary transplantation Transplantation 53 1992 20
52. R.J. Keenan H. Konishi A. Kawai Clinical trial of tacrolimus versus cyclosporine in lung transplantation Ann Thorac Surg 60 1995 580
53. R.J. Keenan A. Zeevi A.T. Iacono Efficacy of inhaled cyclosporine in lung transplant recipients with refractory rejection: Correlation of intragraft cytokine gene expression with pulmonary function and histologic characteristics Surgery 118 1995 385
54. C.A. Keller P.T. Cagle R.W. Brown Bronchiolitis obliterans in recipients of single, double, and heart–lung transplantation Chest 107 1995 973
55. J.A. Kimball M.D. Pescovitz B.K. Book Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil Transplantation 60 1995 1379
56. T. Kino T. Goto Discovery of FK-506 and update Ann N Y Acad Sci 685 1993 13
57. G.B. Klintmalm FK 506: An update Clin Transplant 8 1994 207
58. S.J. Knechtle J. Wang W.J. Burlingham The influence of RS-61443 on antibody-mediated rejection Transplantation 53 1992 699
59. C.C. Kuchle G.H. Thoenes K.H. Langer Prevention of kidney and skin-graft rejection in rats by leflunomide, a new immunomodulating agent Transplant Proc 23 1991 1083
60. W.A. Lee L. Gu A.R. Miksztal Bioavailability improvement of mycophenolic acid through amino ester derivatization Pharm Res 7 1990 161
61. R.A. Lirtzman C.R. Gregory R.E. Levitski Combined immunosuppression with leflunomide and cyclosporine prevents MLR-mismatched renal allograft rejection in a mongrel canine model Transplant Proc 28 1996 945
62. J. Liu FK506 and cyclosporin, molecular probes for studying intracellular signal transduction Immunol Today 14 1993 290 [published erratum appears in Immunol Today 14:399, 1993]
63. C. Loh K.T. Shaw J. Carew Calcineurin binds the transcription factor NFAT1 and reversibly regulates its activity J Biol Chem 271 1996 10884
64. M.C. Lorenz J. Heitman TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin J Biol Chem 270 1995 27531
65. J. Lucien V.C. Dias D.F. Le Gatt Blood distribution and single-dose pharmacokinetics of leflunomide Ther Drug Monit 17 1995 454
66. M. Machida S. Takahara M. Ishibashi Effect of temperature and hematocrit on plasma concentration of FK 506 Transplant Proc 23 1991 2753
67. J.R. Maurer D.E. Tullis R.F. Grossman Infectious complications following isolated lung transplantation Chest 101 1992 1056
68. J. McCauley S. Takaya J. Fung The question of FK 506 nephrotoxicity after liver transplantation Transplant Proc 23 1991 1444
69. L.P. McChesney F. Xiao H.N. Sankary An evaluation of leflunomide in the canine renal transplantation model Transplantation 57 1994 1717
70. P. McMaster D.F. Mirza T. Ismail Therapeutic drug monitoring of tacrolimus in clinical transplantation Ther Drug Monit 17 1995 602
71. B.M. Meiser M.E. Billingham R.E. Morris Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease Lancet 338 1991 1297
72. J.D. Miller G.A. Patterson Retransplantation following isolated lung transplantation Semin Thorac Cardiovasc Surg 4 1992 122
73. A. Mitsui S. Suzuki Immunosuppressive effect of mycophenolic acid J Antibiot (Tokyo) 22 1969 358
74. V. Mladenovic Z. Domljan B. Rozman Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study Arthritis Rheum 38 1995 1595
75. K.W. Mollison T.A. Fey R.A. Krause Comparison of FK-506, rapamycin, ascomycin, and cyclosporine in mouse models of host-versus-graft disease and heterotopic heart transplantation Ann N Y Acad Sci 685 1993 55
76. R.E. Morris Rapamycins: Antifungal, antitumor, antiproliferative and immunosuppressive macrolides Transplant Rev 6 1992 39
77. R.E. Morris R.W. Busuttil G.B. Klintmalm Transplantation of the Liver 1995 WB Saunders Philadelphia 760 786
78. R.E. Morris Mechanism of action of new immunosuppressive drugs Kidney Int Suppl 49 1996 S26
79. R.E. Morris B.M. Meiser Identification of a new pharmocologic action for an old compound Med Sci Res 17 1989 609
80. R.E. Morris B.W. Brown Jr Tacrolimus for prevention of liver allograft rejection: Clinical trials and tribulations Lancet 346 1995 1310
81. R.E. Morris E.G. Hoyt E.M. Eugui Prolongation of rat heart allograft survival by RS-61443 Surg Forum 40 1989 337
82. R.E. Morris E.G. Hoyt M.P. Murphy Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis Transplant Proc 22 1990 1659
83. R.E. Morris X. Huang W. Cao Leflunomide (HWA 486) and its analogues suppress T- and B-cell proliferation in vitro, acute rejection, ongoing rejection, and antidonor antibody synthesis in mouse, rat, and cynomolgus monkey transplant recipients as well as arterial intimal thickening after balloon catheter injury Transplant Proc 27 1995 445
84. R.E. Morris X. Huang C.R. Gregory Studies in experimental models of chronic rejection: Use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis Transplant Proc 27 1995 2068
85. R.E. Morris B.M. Meiser J. Wu Use of rapamycin for the suppression of alloimmune reactions in vivo: Schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions Transplant Proc 23 1991 521
86. R.E. Morris J. Wang J.R. Blum Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts Transplant Proc 23 1991 19
87. R.E. Morris J. Wu R. Shorthouse A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection Transplant Proc 22 1990 1638
88. A.R. Mueller K.P. Platz W.O. Bechstein Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506 Transplantation 58 1994 155
89. M.G. Murgia S. Jordan B.D. Kahan The side-effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone treated renal transplant patients Kidney Int 49 1995 209
90. J. Nakajima The immunosuppressive effects of FK506 on single lung allotransplantation in Japanese monkey (Macaca fuscata) Nippon Kyobu Geka Gakkai Zasshi 41 1993 1172
91. T.G. O'Riordan A. Iacono R.J. Keenan Delivery and distribution of aerosolized cyclosporine in lung allograft recipients Am J Respir Crit Care Med 151 1995 516
92. J. Parameshwar L. Sharples P. Schofield Can steroids be successfully withdrawn in heart transplant recipients? J Heart Lung Transplant 14 1995 S85
93. G.J. Peters J.H. Veerkamp Purine and pyrimidine metabolism in peripheral blood lymphocytes Int J Biochem 15 1983 115
94. K.P. Platz A.R. Mueller G. Blumhardt Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506 Transplantation 58 1994 170
95. K.P. Platz H.W. Sollinger D.A. Hullett RS-61443: A new, potent immunosuppressive agent Transplantation 51 1990 27
96. J.T. Ransom Mechanism of action of mycophenolate mofetil Ther Drug Monit 17 1995 681
97. H. Reichenspurner R.E. Girgis R.C. Robbins Obliterative bronchiolitis after lung and heart–lung transplantation Ann Thorac Surg 60 1995 1845
98. H. Reichenspurner X. Huang V. Soni Pathogenesis and treatment of obliterative airway disease after heterotopic tracheal allograft and xenograft transplantation Surg Forum 46 1995 456
99. H. Ross L. Gullestad J. Pak Methotrexate and total lymphoid radiation are equally effective for treatment of recurrent rejection J Heart Lung Transplant 15 1996 S95
100. M.M. Salter J.K. Kirklin R.C. Bourge Total lymphoid irradiation in the treatment of early or recurrent heart rejection J Heart Lung Transplant 11 1992 902
101. R. Sangrigoli I.L. Pina K.B. Margulies Methotrexate adjuvant immunosuppression for cardiac transplant recipients with frequent rejection episodes: Reduction of significant rejection frequency and steroid dose J Heart Lung Transplant 14 1995 S98
102. L.M. Shaw H.W. Sollinger P. Halloran Mycophenolate mofetil: A report of the consensus panel Ther Drug Monit 17 1995 690
103. K.F. Siemasko A.S. Chong J.W. Williams Regulation of B-cell function by the immunosuppressive agent leflunomide Transplantation 61 1996 635
104. N.H. Sigal F.J. Dumont Cyclosporin A, FK-506, and rapamycin: Pharmacologic probes of lymphocyte signal transduction Annu Rev Immunol 10 1992 51
105. H.T. Silva R. Shorthouse R.E. Morris Single- and multiple-dose pharmacokinetics and pharmacodynamics of leflunomide's active metabolite A77 1726 in normal Lewis rats Transplant Proc 28 1996 3092 3094
106. M.D. Sintchak M.A. Fleming O. Futer Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid Cell 85 1996 921
107. H.W. Sollinger Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group Transplantation 60 1995 225
108. H.W. Sollinger F.O. Belzer M.H. Deierhoi RS-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection Ann Surg 216 1992 513
109. H.W. Sollinger M.H. Deierhoi F.O. Belzer RS-61443—a phase I clinical trial and pilot rescue study Transplantation 53 1992 428
110. T.E. Starzl A. Donner M. Eliasziw Randomised trialomania? The multicentre liver transplant trials of tacrolimus Lancet 346 1995 1346
111. D.M. Steele D.A. Hullett W.O. Bechstein Effects of immunosuppressive therapy on the rat aortic allograft model Transplant Proc 25 1993 754
112. F. Streit U. Christians H.M. Scheibel Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray—mass spectrometry Clin Chem 42 1996 1417 1425
113. N. Terada J.J. Lucas A. Szepesi Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells Biochem Biophys Res Commun 186 1992 1315
114. G.H. Thoenes T. Sitter K.H. Langer Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats Int J Immunopharmacol 11 1989 921
115. A.W. Thomson J. Woo G.Z. Yao Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T-cell activation molecule expression in human mixed lymphocyte cultures Transplant Immunol 1 1993 146
116. R. Venkataramanan A. Jain V.S. Warty Pharmacokinetics of FK 506 in transplant patients Transplant Proc 23 1991 2736
117. P.H. Whiting J. Woo B.J. Adam Toxicity of rapamycin—a comparative and combination study with cyclosporine at immunotherapeutic dosage in the rat Transplantation 52 1991 203
118. G. Wiederrecht E. Lam S. Hung The mechanism of action of FK-506 and cyclosporin A Ann N Y Acad Sci 696 1993 9
119. J.W. Williams F. Xiao P. Foster Leflunomide in experimental transplantation. Control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine Transplantation 57 1994 1223
120. M. Winkler B. Ringe J. Baumann Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK 506 for immunosuppression Clin Chem 40 1994 2247
121. F. Xiao A.S. Chong P. Foster Leflunomide controls rejection in hamster to rat cardiac xenografts Transplantation 58 1994 828
122. X. Xu J.W. Williams E.G. Bremer Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide J Biol Chem 270 1995 12398
123. R.W. Yatscoff C. Faraci P. Bolingbroke Measurement of rapamycin in whole blood using reverse-phase high-performance liquid chromatography Ther Drug Monit 14 1992 138
124. R.W. Yatscoff P. Wang K. Chan Rapamycin: Distribution, pharmacokinetics, and therapeutic range investigations Ther Drug Monit 17 1995 666
125. D.D. Yuh K.L. Gandy R.E. Morris Leflunomide prolongs pulmonary allograft and xenograft survival J Heart Lung Transplant 14 1995 1136
126. M. Zenati A.J. Duncan G.J. Burckart Immunosuppression with aerosolized cyclosporine for prevention of lung rejection in a rat model Eur J Cardiothorac Surg 5 1991 266
127. T. Zielinski D. Zeitter S. Muller Leflunomide, a reversible inhibitor of pyrimidine biosynthesis? Inflammation Research 44 suppl 2 1995 S207